Orlando, Florida, Wednesday, March 3, 2022
Today we are extremely honored to share Florida Retina Institute’s Matthew A. Cunningham, MD, and his research team are the first to enroll a patient in the United States into the ML43435/Elevatum study.
Elevatum is a USMA sponsored PhIV study with faricimab (VABYSMO) for underrepresented patients with Diabetic Macular Edema, DME.
It is the first inclusive research study for Ophthalmology.
The impact of Elevatum in our patient populations spans beyond the expansion of our understanding about faricimab.
Faricimab is the first investigational bispecific antibody designed for the eye.
Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor, and angiopoietin 2 inhibitor.
Matthew A. Cunningham, MD, is the Primary Investigator and Clinical Research Director, Central Florida Region Clinical Research, Florida Retina Institute
For more information about clinical trials or if you should have any questions, please feel free to contact us.
Jacksonville Oak Street
Jacksonville Perimeter Park
Mondays - Fridays: 8AM to 5PM
Saturdays - Sundays: Closed
In Case of Emergency: 911